MCAS: The Step-Up Treatment Approach
Lawrence Afrin, MD, sole author of the first textbook on mast cell activation syndrome (MCAS) and one of the field's most-published clinician-researchers, describes a step-up approach: starting with OTC H1 and H2 antihistamines (for example cetirizine plus famotidine) as first-line, then mast-cell-stabilizer supplements such as quercetin as a thin-evidence adjunct, with anything beyond that (ketotifen, cromolyn, biologics) as physician-directed only, never self-started. MCAS itself remains a genuinely contested diagnosis outside stricter, tryptase-based Consensus-2 criteria; that tension is real and this page states it plainly rather than as settled.
Try a non-sedating H1 antihistamine such as cetirizine Per label, commonly 10mg once daily; discuss with your clinician before combining with other medications
H1 blockade addresses one class of mast-cell mediator effects (itching, flushing, hives) and is Afrin's published first-line step.
Pair with an H2 antihistamine such as famotidine Per label, commonly 10-20mg once or twice daily; discuss with your clinician before combining, especially alongside other medications
H1 and H2 antihistamines block different mast-cell-mediator effects, and Afrin's published algorithm pairs them as the first-line step rather than using either alone.
Some patients try quercetin as a mast-cell-stabilizer adjunct alongside the antihistamine pair Per label
Quercetin has preclinical mast-cell-stabilizing evidence; it is a commonly-tried adjunct, not a core part of Afrin's published algorithm, and the evidence for the MCAS-specific use case is thin.
Some patients with histamine-intolerance-adjacent symptoms try a DAO enzyme supplement with meals Per label, taken with meals
Evidence for DAO supplementation is preliminary and histamine intolerance is itself a contested diagnosis distinct from MCAS. This is a commonly-tried option, not part of Afrin's own published protocol, and is graded separately and honestly here.
Prescription mast-cell stabilizers (ketotifen, cromolyn) and biologics are Afrin's next steps, and are never self-started n/a, physician-prescribed and monitored
These options need dosing and monitoring by a clinician experienced with MCAS.
Afrin's published step-up algorithm starts with the lowest-risk, most accessible interventions (OTC antihistamines blocking H1 and H2 receptors, which cover different mast-cell-mediator effects) before escalating to prescription mast-cell stabilizers or biologics, which need physician oversight for dosing and monitoring.
View sources
Dr. Ruscio Radio: Mast Cell Activation Syndrome with Dr. Lawrence Afrin, Part 1
Dr. Ruscio Radio: Mast Cell Activation Syndrome with Dr. Lawrence Afrin, Part 2
Presentation, diagnosis, and management of mast cell activation syndrome
Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Independent curation. YourProtocol is an independent platform. This protocol is based on the publicly available work of Lawrence Afrin, MD and is not created, reviewed, endorsed by, or affiliated with Lawrence Afrin, MD or AIM Center for Personalized Medicine.
Is this for you
- People with flushing, hives, GI symptoms, or lightheadedness that seem triggered by food, temperature, stress, or exertion
- Anyone exploring an MCAS diagnosis alongside POTS or ME/CFS
- Readers who want the honest state of MCAS diagnostic disagreement, not a settled answer
Cautions
- Informational only, alongside your physician's care
- MCAS itself is a genuinely contested diagnosis outside stricter Consensus-2 criteria
- Never self-start a prescription mast-cell stabilizer or biologic; that step is physician-directed only
Some links earn us a commission. It never affects our picks or grades. See our affiliate disclosure.